# Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

> **NCT00039000** · PHASE3 · COMPLETED · sponsor: **Agenus Inc.** · enrollment: 350 (—)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** HSPPC-96 or Oncophage

## Key facts

- **NCT ID:** NCT00039000
- **Lead sponsor:** Agenus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 350 (—)
- **Last updated:** 2012-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039000, "Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00039000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*